Universität zu Köln

2017

Al-Sawaf, O., Robrecht, S., Bahlo, J., Fink, A. M., Cramer, P., von Tresckow, J., Maurer, C., Bergmann, M., Seiler, T., Lange, E., Kneba, M., Stilgenbauer, S., Doehner, H., Kiehl, M. G., Jaeger, U., Wendtner, C. M., Fischer, K., Goede, V., Hallek, M., Eichhorst, B. and Hopfinger, G. (2017). Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group. Leukemia, 31 (10). S. 2251 - 2255. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

2016

Al-Sawaf, O., Kluth, S., Bahlo, J., Hopfinger, G., Fink, A. M., Cramer, P., Maurer, C., Bergmann, M., Dreyling, M., Lange, E., Kneba, M., Stilgenbauer, S., Kiehl, M. G., Jaeger, U., Wendtner, C. M., Fischer, K., Hallek, M. and Eichhorst, B. (2016). Impact of gender on outcome after chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) or bendamustin plus R (BR) in CLL patients: a pooled analysis of the German CLL Study Group (GCLLSG). Oncol. Res. Treat., 39. S. 212 - 214. BASEL: KARGER. ISSN 2296-5262

Bahlo, J., Goede, V, Kutsch, N., Fischer, K., Fink, A. -M, Stilgenbauer, S., Bergmann, M., Eichhorst, B. and Hallek, M. (2016). Evaluation of the international prognostic index for chronic lymphocytic leukemia (CLL-IPI) in elderly patients with comorbidities: Analysis of the CLL11 study population. Oncol. Res. Treat., 39. S. 5 - 7. BASEL: KARGER. ISSN 2296-5262

2015

Bahlo, J., Kutsch, N., Bergmann, M., Byrd, J., Doehner, H., Eichhorst, B., Else, M., Geisler, C., Grever, M., Lepretre, S., Neuberg, D., Oscier, D., Robak, T., Rosenquist, R., Shanafelt, T., Stilgenbauer, S. and Hallek, M. (2015). THE INTERNATIONAL PROGNOSTIC INDEX FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL-IPI)-AN INTERNATIONAL META-ANALYSIS. Haematologica, 100. S. 313 - 315. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Pflug, N., Maurer, C., Bahlo, J., Kluth, S., Rhein, C., Cramer, P., Gross-Ophoff, C., Langerbeins, P., Fink, A. -M., Eichhorst, B., Kreuzer, K. -A., Tausch, E., Stilgenbauer, S., Boettcher, S., Doehner, H., Kneba, M., Hallek, M., Wendtner, C. -M., Bergmann, M. and Fischer, K. (2015). Bendamustine and Rituximab in combination with Lenalidomide in patients with relapsed or refractory and in patients with previously untreated chronic lymphocytic leukemia: A multicenter phase I/II safety and efficacy trial of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG). Oncol. Res. Treat., 38. S. 92 - 93. BASEL: KARGER. ISSN 2296-5262

2010

Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A. M., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Gruenhagen, U., Bergmann, M., Catalano, J., Zinzani, P. L., Caligaris-Cappio, F., Seymour, J. F., Berrebi, A., Jaeger, U., Cazin, B., Trneny, M., Westermann, A., Wendtner, C. M., Eichhorst, B. F., Staib, P., Buehler, A., Winkler, D., Zenz, T., Boettcher, S., Ritgen, M., Mendila, M., Kneba, M., Doehner, H. and Stilgenbauer, S. (2010). Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet, 376 (9747). S. 1164 - 1175. NEW YORK: ELSEVIER SCIENCE INC. ISSN 0140-6736